Reported about 15 hours ago
A leading Wall Street analyst has suggested investors move away from the declining Magnificent Seven tech stocks and consider three strong pharmaceutical companies for potential growth and dividends. The Magnificent Seven, largely driven by AI advancements, face increasing costs and profit pressures due to anticipated tariffs on Chinese imports. In contrast, Merck, Bristol Myers Squibb, and AbbVie are highlighted for their stable revenue prospects, substantial dividends, and potential for future growth, making them attractive options for investors seeking reliable income.
Source: YAHOO